跳至主要内容
临床试验/ACTRN12621000815864
ACTRN12621000815864招募中未知

Does therapeutic plasma exchange improve outcomes in severe Guillain-Barre Syndrome (GBS) compared to intravenous immunoglobulin? A protocol for a New Zealand pilot study

Waikato Hospital0 个研究点目标入组 50 人开始时间: 2021年6月28日最近更新:

试验速览

阶段
未知
状态
招募中
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1)A diagnosis of GBS by Cornblath and Asbury criteria .
  • 2)GBS severity of 4 or 5 by Hughes GBS severity scale OR early treatment outcome (EGOS) score of 5 or greater OR early GBS respiratory insufficiency (EGRIS) score of 5 or greater.
  • 3)Able to start assigned treatment within 2 weeks of weakness onset.
  • 4)At least 18 years of age at the time of enrollment.
  • 5)Able to provide informed consent

排除标准

  • 1) Any antecedent illness that would interfere with the ability to perform outcome assessments
  • 2)History of an allergy to IVIg
  • 3)History of an allergic reaction to Albumin 4%.
  • 4)History of IgA deficiency with anti-IgA antibodies
  • 5)Known reaction to blood products
  • 6)Patient with strong objection to the use of blood products

研究者

相似试验